What is Exicure?
Exicure operates at the intersection of advanced molecular biology and therapeutic development. The company is primarily focused on the commercialization of its proprietary Spherical Nucleic Acid (SNA) platform, which offers chemical and biological properties that differentiate it from traditional nucleic acid delivery systems. By targeting disease pathways that have historically remained elusive to conventional pharmaceutical interventions, Exicure maintains a specialized market position. Its development-stage pipeline is designed to address high-unmet-need conditions, particularly within the neurology sector, where the precision of SNA technology provides a competitive edge in therapeutic efficacy and cellular uptake.
How much funding has Exicure raised?
Exicure has raised a total of $116.9M across 11 funding rounds:
Series B
$5.4M
Series C
$13.6M
Other Financing Round
$14.8M
Share Placement
$20M
Share Placement
$11.2M
Debt
$350K
Debt
$25M
Private Equity
$5.4M
Private Equity
$10M
Share Placement
$8.7M
Series B (2012): $5.4M led by Patrick Ryan, Abbott Biotech Ventures, David R. Walt, Craig Mundie, and Eric Schmidt
Series C (2014): $13.6M supported by Craig Mundie, Boon Hwee Koh, Bill Gates, and Patrick Ryan
Other Financing Round (2015): $14.8M featuring Tempus and Liz Lefkofsky
Share Placement (2017): $20M backed by Patrick G. Ryan, Katalyst Securities, Craig Mundie, AbbVie, David R. Walt, Mark Tompkins, and Tempus
Share Placement (2017): $11.2M with participation from Luye Pharma Group
Debt (2020): $350K led by PPP
Debt (2020): $25M, investors not publicly disclosed
Private Equity (2022): $5.4M featuring CBI USA
Private Equity (2024): $10M backed by Hitron Systems
Share Placement (2024): $8.7M, investors not publicly disclosed
Key Investors in Exicure
Abbott Biotech Ventures
A specialized venture arm of a global biopharmaceutical leader, focusing on high-potential research and development initiatives in the life sciences sector.
Luye Pharma Group
An international pharmaceutical entity with a strategic emphasis on central nervous system disorders, oncology, and innovative medication development.
Bill Gates
A prominent private investor and philanthropist known for supporting transformative technologies that address global health and complex medical challenges.
What's next for Exicure?
With the infusion of $8.7M, Exicure is well-positioned to accelerate its clinical development programs and refine its manufacturing capabilities. The company's strategic roadmap focuses on validating the therapeutic potential of its SNA platform through rigorous clinical trials and expanding its intellectual property portfolio. As the firm transitions from early-stage research toward more mature clinical milestones, the focus will likely shift toward strategic partnerships and potential licensing agreements to scale its reach. The continued backing from a diverse group of investors suggests a long-term commitment to the company's vision of redefining genetic medicine through its innovative, proprietary architecture.
See full Exicure company page
